ClinicaliQ Trial Snapshot
- Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy — Recruiting • Phase II / Phase III • Neurology • NCT06309966.
- BHV-7000 is being tested to see if it works safely in adults with focal epilepsy that doesn't respond to current drugs.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy. Conditions: Focal Epilepsy Interventions: BHV-7000, BHV-7000, Placebo Lead Sponsor: Biohaven Therapeutics Ltd. Planned Enrollment: 390 participants